Investigational Tau Modifier Receives Orphan Drug Status for Progressive Supranuclear Palsy

 

The Food and Drug Administration (FDA) has granted an orphan drug designation to ASN120290 (Asceneuron SA, Lausanne, Switzerland) for the treatment of progressive supranuclear palsy (PSP). In preclinical studies, ASN120290 substantially reduced the build-up of toxic tau aggregates and formation of neurofibrillary tangles, thought to be a key driver of neurodegeneration in multiple forms of dementia, including Alzheimer’s disease and Parkinson’s disease.

ASN120290 is a selective inhibitor of the glycoside hydrolase, O-GlcNAcase, with the potential to become a first-in class-treatment for PSP and other neurodegenerative diseases in which tau plays a pathophysiology role.

A randomized, double-blind, placebo-controlled phase 1 trial of ASN120290 study assessing safety and tolerability of single and multiple doses in healthy volunteers has been completed. Data from that study will be presented at the upcoming Alzheimer's Association International Conference (AAIC) in Chicago July 22-26, 2018.

Dirk Beher, Chief Executive Officer and a founder of Asceneuron, commented: "PSP is a rare neurological condition for which there is currently no treatment available. ASN120290 is an orally bioavailable molecule that has the potential of treating the root cause of the neurodegeneration. (This) is an important milestone for the team and the company."

Orphan drug status is intended to advance drug development for rare diseases and is granted to drugs and biologics that demonstrate promise for the diagnosis and/or treatment of rare diseases. Orphan drug development includes FDA assistance in clinical trial design and an exemption from FDA user fees.

 

Contact Info

For advertising rates and opportunities:
Wendy Terry
Publisher
217-652-3859
wterry@bmctoday.com

About Practical Neurology

Launched in 2002, Practical Neurology is a publication uniquely dedicated to presenting current approaches to patient management, synthesis of emerging research and data, and analysis of industry news with a goal to facilitate practical application and improved clinical practice for all neurologists. Our straightforward articles give neurologists tools they can immediately put into practice.

 
  • BRYN MAWR COMMUNICATIONS III, LLC